Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics in Drug Discovery

Scott Ribich's Biography

Scott Ribich, Associate Director, Epizyme

Dr. Ribich is an Associate Director in the Biological Sciences Department at Epizyme, a clinical stage biopharmaceutical company that creates novel epigenetic therapies for cancer patients. Dr. Ribich received his BS in Biology from MIT, and his Ph.D in Biochemistry from Harvard University in 2005 in the laboratory of Professor Thomas Maniatis. He completed his postdoctoral training at Brigham and Women’s Hospital in 2008 with Professor Antonio Bianco. Both his graduate and postgraduate work focused on the molecular biology and epigenetics underlying disease and development. In 2008, he joined Sirtris, a GlaxoSmithKline company, which developed metabolic disease therapeutics targeting the sirtuin family of deacteylases. He has worked at Epizyme since 2011, where his group focuses on the role of the histone methyltransferase EZH2 in various oncology indications.

Scott Ribich Image

The Emerging Translational Landscape for EPZ-6438, A Small Molecule Inhibitor of EZH2

Wednesday, 27 January 2016 at 09:30

Add to Calendar ▼2016-01-27 09:30:002016-01-27 10:30:00Europe/LondonThe Emerging Translational Landscape for EPZ-6438, A Small Molecule Inhibitor of EZH2Epigenetics in Drug Discovery in Cambridge, UKCambridge,

Tazemetostat (EPZ-6438) is a small molecule inhibitor of EZH2 developed by Epizyme that is currently in early clinical development for the treatment of various cancer types. In this talk, the preclinical properties, emerging oncology landscape, and early clinical experience with tazemetostat will be discussed.

Add to Calendar ▼2016-01-26 00:00:002016-01-27 00:00:00Europe/LondonEpigenetics in Drug DiscoveryEpigenetics in Drug Discovery in Cambridge, UKCambridge,